Objectives: C-reactive protein (CRP) is an established marker for systemic inflammation in dogs that is especially elevated in dogs with sepsis. Some dogs with acute hemorrhagic diarrhea syndrome (AHDS) develop bacterial translocation and consequent sepsis during hospitalization. This study aimed to evaluate the course of CRP plasma concentrations during hospitalization and its correlation with clinical and other laboratory variables in dogs with AHDS.Methods: In this prospective, observational study, CRP was evaluated on days 0, 1, 2, and 3 in 27 client-owned dogs who presented with AHDS. Clinical examination data, blood pressure, acute patient physiologic and laboratory evaluation (APPLE) full and APPLE fast scores, and canine hemorrhagic diarrhea severity (CHDS) index were measured on the same days to evaluate the severity of the disease.Results: Twenty-five of the 27 dogs were discharged from hospital. Nineteen dogs received antimicrobial treatment due to sepsis or neutropenia. CRP values were mildly elevated on day 0 (median 27.3 mg/L; 1.0–125.8 mg/L) and markedly elevated on day 1 (median 88.9 mg/L; 1.4–192.7 mg/L). CRP concentrations decreased gradually over the following days. Moreover, CRP concentrations correlated moderately with albumin, leucocyte count, neutrophil count, and APPLE full and fast scores, but not with antimicrobial treatment.Conclusion and relevance: CRP concentrations were significantly elevated in patients with AHDS. In this study population, CRP did not help in detecting the requirement of antimicrobial treatment in dogs with AHDS. Nevertheless, as CRP can monitor the response to treatment, regular analysis can guide treatment.
27 July 2021 in Journal of Feline Medicine and Surgery
Ultrasonography of the caudal vena cava (CVC) has been previously established to assess fluid status in dogs but not in cats. The aim of this study was to determine CVC diameter changes during feline blood donation. Inter- and intra-observer variability were assessed in 11 client-owned cats. Minimal and maximal CVC diameters were assessed longitudinally in the subxiphoid view (SV) and right paralumbar view (PV), and transversely in the right hepatic intercostal view (HV). Eighteen client-owned, healthy, anaesthetised cats were evaluated during 21 blood donation procedures of 10 ml/kg in the same anatomical locations before (T0) and after (T1) blood donation, and after volume resuscitation with 30 ml/kg lactated Ringer’s solution (T2). The CVC index was calculated. Intra-observer variability was acceptable for all probe positions, except for the HV, whereas inter-observer variability was considered unacceptable for all probe positions. Complete measurements were obtained during 21 blood donations at T0, T1 and T2 at the SV, during 18/21 blood donations at the HV and during 16/21 blood donations at the PV. At the SV, the minimal CVC diameter between T1 and T2 (P <0.001), and the maximal CVC diameter between T0 and T1 and between T1 and T2 (P <0.001) were significantly different. At the HV, the minimal vertical diameter, maximal vertical diameter and minimal horizontal diameter were different between all timepoints (P <0.001). The maximal horizontal diameter was different between T1 and T2 (P = 0.002). At the PV, both diameters were different between all timepoints (P <0.001). The CVC index was not different between timepoints. Significant probe position dependent CVC diameter changes with marked overlap were observed before and after blood donation, and after fluid bolus. No absolute CVC diameter could be used to indicate hypovolaemia. Ultrasonographic assessment of the feline CVC is highly operator-dependent. The CVC index is not useful in cats.
A three-year-old, intact female mix-breed dog, weighing 30 kg, was presented due to vomitus and diarrhea. At presentation, the patient had a slightly reduced general condition and moderately enlarged mandibular and popliteal lymph nodes. The initial blood work showed severe azotemia and hypoalbuminemia. In the urinalysis, marked proteinuria with a urine protein/creatinine ratio (UPC) of 4.69 was found. Further workup showed a high leishmania antibody titer. The dog was diagnosed with leishmaniosis and glomerulonephritis. Initial treatment consisted of intravenous fluid therapy, allopurinol, miltefosine, amlodipine, clopidogrel, and a diet with a low purine content. Creatinine temporarily decreased but increased again after three days. For further supportive treatment, intermittent hemodialysis in combination with hemoperfusion with the cytosorb® adsorber was performed. A total blood volume of 17.7 L was processed within three hours. Thereafter, immunoadsorption (IA) was performed with the COM.TEC® and ADAsorb® platforms and a LIGASORB® adsorber to eliminate circulating immunocomplexes. Treatment time for IA was two hours with a blood flow of 50 mL/min. A total plasma volume of 2.4 L was processed. Over the following days, creatinine declined, and the patient improved significantly. UPC decreased to 1.74 on day 17 after IA. The patient was discharged after two and a half weeks. Two years after the initial event, the patient is still in excellent condition, with creatinine, UPC, and albumin levels in the reference range. Therefore, IA might be an additional therapeutic option for dogs with leishmaniosis-induced glomerulonephritis and subsequent severe azotemia to improve immunocomplex-mediated glomerulonephritis.
A one-year-old, female intact Samoyed, 12.5 kg, was presented with coughing for 2 weeks, progressive appendicular and axial muscle weakness, megaesophagus and labored breathing for 5 days. There was no improvement with standard treatment. Acquired myasthenia gravis was suspected and the dog was referred with increasing dyspnea. At presentation, the dog showed a severely reduced general condition, was non-ambulatory and showed abdominal and severely labored breathing. A marked hypercapnia (PvCO2 = 90.1 mmHg) was present in venous blood gas analysis. The serum anti-acetylcholine receptor antibody test was consistent with acquired myasthenia gravis (2.1 nmol/L). The dog was anesthetized with propofol and mechanically ventilated with a Hamilton C1 ventilator. Immunoadsorption was performed with the COM.TEC® and ADAsorb® platforms and a LIGASORB® adsorber to eliminate anti-acetylcholine receptor antibodies. Local anticoagulation was performed with citrate. Treatment time for immunoadsorption was 1.5 h with a blood flow of 50 mL/min. A total plasma volume of 1.2 L was processed. Further medical treatment included intravenous fluid therapy, maropitant, esomeprazole, antibiotic therapy for aspiration pneumonia and neostigmine 0.04 mg/kg intramuscularly every 6 h for treatment of acquired myasthenia gravis. Mechanical ventilation was stopped after 12 h. A percutaneous gastric feeding tube was inserted under endoscopic control on day 2 for further medical treatment and nutrition. A second treatment with immunoadsorption was performed on day 3. Again, a total plasma volume of 1.2 L was processed. Immediately after this procedure, the dog regained muscle strength and was able to stand and to walk. After 6 days, the dog was discharged from the hospital. This is the first report of immunoadsorption for emergency management of a dog with acute-fulminant acquired myasthenia gravis. Immunoadsorption may be an additional option for emergency treatment in dogs with severe signs of acquired myasthenia gravis.
Cell-free hemoglobin (cfHb) can be toxic and lead to kidney injury. This study assessed the in vitro reduction of cfHb from canine hemolyzed blood using hemoperfusion with a Cytosorb® cytokine adsorber. Canine whole blood was processed in linear and circular setups, with three runs each, at 100 mL/min. Hemolysis and osmolarity adjustments were performed with distilled water and hypertonic saline. Anticoagulation was optimized with heparin (10,000 IU/L). A median of 3.38 L of hemoglobin solution was processed in the linear setup. Samples were collected after the adsorber and from the waste bag. In the circular setup, a median of 2.09 L was processed, with samples taken before and after the adsorber. CfHb concentration was measured using the XT-2000iV® hematology analyzer (Sysmex). A control setup without an adsorber was run for 24 hours to assess cfHb stability. In the linear setup, cfHb concentration decreased by a median of 17.8% (14.7–26.8%), from 1.7 mmol/L to a minimum of 0.9 mmol/L, with 12.1 g (11.9–23.5 g) of cfHb removed. The median cfHb concentration after the adsorber displayed a logarithmic increase from 0.9 mmol/L (0.8–1.2 mmol/L) to 1.6 mmol/L (1.4–2.1 mmol/L). After processing 2.4 L, no further reduction occurred. In the circular setup, cfHb was reduced by a median of 41.3% (46.1–45.0%), representing 17.4 g (14.6–19.0 g) removed after 13.0 L (13.0–14.0 L). The reduction plateau was reached after 13 L. The hemoglobin reduction ratio in the circular setup at 3 L processed cfHb-solution was 25.0% (23.1–33.3%) and was not different from the linear setup (p = 0.400). The cfHb clearance decreased in both setups over time. CfHb concentration in the control setup was stable for 24 hours. Hemoperfusion with the Cytosorb® adsorber reduced cfHb in vitro from a canine blood solution.
13 October 2025 in Frontiers in Veterinary Science
A six-year-old, intact male German Shepherd, weighing 43 kg, was presented with generalized edema formation and acute kidney injury due to a suspected delayed type III hypersensitivity reaction and vasculitis 2 weeks after the administration of human serum albumin (HSA). At presentation, the patient had a moderately reduced general condition, a heart rate of 96/min, rectal temperature of 37.0 °C, generalized edema, hematoma and petechiae on all limbs and the abdomen, and scleral hemorrhage. The initial blood work showed a moderate anemia, a severe azotemia, and a moderate hypoalbuminemia. Marked proteinuria with a urine protein-creatinine ratio (UPC) of 6.26 was present. The presence of anti-HSA antibodies was proven with an in-house ELISA. For treatment, immunoadsorption (IA) was performed with the TheraSorb® Ig Omni 1 adsorber, which was integrated in the LIFE 21® apheresis unit. Due to severe azotemia, an intermittent hemodialysis treatment with the dialysis platform Fresenius 4008 was performed after IA. Both treatments were repeated on the following day. A total plasma volume of 1.9 liters and 3.7 liters, respectively, was processed with IA. On the following days, creatinine concentration declined and the patient improved significantly. The patient was discharged after 10 days. UPC decreased to 0.82 and edema completely resolved. Two weeks after discharge, Creatinine, UPC and albumin were in the reference range. IA might be an additional therapeutic option for dogs with severe acute kidney injury due to a suspected delayed type III hypersensitivity reaction.